In a conti'olled stucly, inpatient violence was measured cluring placebo, high-potency (halopericlol) and lorv-potency (chlorpromazine or clozapine) neuroleptics. Some patients had a markecl increase in violent behavior rvith the mocleratelv high-dose haloperidol, but not u,ith lou,-potency neuroleptics. The authors cliscuss reasons for the inct'easecl vioience rvith halopericlol, inclucling al

A retrospective review was conducted to assess the effect of molindone on weight. Monthly weights and neuroleptic dosages during the first three months of psychiatric hospitalization were compared between matched groups of patients receiving molindone, a combination of molindone and other neuroleptics, or other neuroleptic drugs. We found no significant differences in weight gain among the three groups. Our results challenge the common opinion that molindone can be associated with a lack of weight gain compared to other antipsychotics.

No abstract